ID

38074

Description

Two-Part Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Pharmacodynamics of Repeat Oral Dosesof the Enteric-Coated Free Base Formulation of Darapladib (SB-480848) ina Dose Rising Fashion and to Evaluate the Safety, Tolerability and Pharmacokinetics of Darapladib when Co-administered with Ketoconazole in Healthy Adult Subjects. There are 4 parts to this study: Screening, Part A, Part B, and Follow-Up. Part A contains 2 Sessions per day for day 1-10, Part B contains 1 Session per day for day 1-14. Each itemgroup contains information when it should be filled out. The itemgroups of the non-serious and serious adverse event forms contain additional information on the definition of a serious/non-serious adverse event.

Mots-clés

Versions (1)
  1. 15/09/2019 15/09/2019 -
Détendeur de droits

GlaxoSmithKline

Téléchargé le

15 septembre 2019

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Darapladib Evaluation Case Report Form GSK LPL107988

Anglais

Serious Adverse Events

12 Formulaires  
Administrative documentation
Description

Administrative documentation

Alias
UMLS CUI-1
C1320722
Subject Identifier
Description

Subject Identifier

Type de données

text

Alias
UMLS CUI [1]
C2348585
Visit Date
Description

Visit Date

Type de données

date

Alias
UMLS CUI [1]
C1320303
Serious adverse event
Description

Serious adverse event

Alias
UMLS CUI-1
C1519255
Did the subject experience a serious adverse event during the study?
Description

Serious adverse event

Type de données

boolean

Alias
UMLS CUI [1,1]
C1519255
UMLS CUI [1,2]
C0681850
UMLS CUI [1,3]
C2745955
Serious adverse event list
Description

Serious adverse event list

Alias
UMLS CUI-1
C1519255
UMLS CUI-2
C0745732
Event
Description

Event

Type de données

text

Alias
UMLS CUI [1,1]
C1519255
UMLS CUI [1,2]
C0027365
Start Date and Time
Description

Start Date and Time

Type de données

datetime

Alias
UMLS CUI [1,1]
C0808070
UMLS CUI [1,2]
C1519255
UMLS CUI [2,1]
C1301880
UMLS CUI [2,2]
C1519255
Outcome
Description

Outcome

Type de données

integer

Alias
UMLS CUI [1,1]
C1519255
UMLS CUI [1,2]
C1274040
End Date and Time
Description

If fatal, record date/time of death.

Type de données

datetime

Alias
UMLS CUI [1,1]
C1519255
UMLS CUI [1,2]
C0806020
UMLS CUI [2,1]
C1522314
UMLS CUI [2,2]
C1519255
Maximum Intensity
Description

Maximum Intensity

Type de données

text

Alias
UMLS CUI [1,1]
C1519255
UMLS CUI [1,2]
C1522410
UMLS CUI [1,3]
C0518690
Action Taken with Investigational Product(s) as a Result of the SAE
Description

Action Taken with Investigational Product(s) as a Result of the SAE

Type de données

text

Alias
UMLS CUI [1,1]
C1547656
UMLS CUI [1,2]
C4688482
UMLS CUI [1,3]
C1519255
Did the subject withdraw from study as a result of this SAE?
Description

Withdrawal

Type de données

boolean

Alias
UMLS CUI [1,1]
C1547656
UMLS CUI [1,2]
C1710677
UMLS CUI [1,3]
C1519255
Is there a reasonable possibility the SAE may have been caused by the investigational product?
Description

Relationship to Investigational Product(s)

Type de données

boolean

Alias
UMLS CUI [1,1]
C0332149
UMLS CUI [1,2]
C4688482
UMLS CUI [1,3]
C0678227
UMLS CUI [1,4]
C1519255
Retour au début de la page

Similar models

Serious Adverse Events

12 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Administrative documentation
C1320722 (UMLS CUI-1)
Subject Identifier
Item
Subject Identifier
text
C2348585 (UMLS CUI [1])
Visit Date
Item
Visit Date
date
C1320303 (UMLS CUI [1])
Item Group
Serious adverse event
C1519255 (UMLS CUI-1)
Serious adverse event
Item
Did the subject experience a serious adverse event during the study?
boolean
C1519255 (UMLS CUI [1,1])
C0681850 (UMLS CUI [1,2])
C2745955 (UMLS CUI [1,3])
Item Group
Serious adverse event list
C1519255 (UMLS CUI-1)
C0745732 (UMLS CUI-2)
Event
Item
Event
text
C1519255 (UMLS CUI [1,1])
C0027365 (UMLS CUI [1,2])
Start Date and Time
Item
Start Date and Time
datetime
C0808070 (UMLS CUI [1,1])
C1519255 (UMLS CUI [1,2])
C1301880 (UMLS CUI [2,1])
C1519255 (UMLS CUI [2,2])
Item
Outcome
integer
C1519255 (UMLS CUI [1,1])
C1274040 (UMLS CUI [1,2])
Outcome
Code List
Outcome
CL Item
Recovered/ Resolved (1)
CL Item
Recovering/Resolving (2)
CL Item
Notrecovered/Not resolved (3)
CL Item
Recovered/Resolved withsequelae (4)
CL Item
Fatal (5)
End Date and Time
Item
End Date and Time
datetime
C1519255 (UMLS CUI [1,1])
C0806020 (UMLS CUI [1,2])
C1522314 (UMLS CUI [2,1])
C1519255 (UMLS CUI [2,2])
Item
Maximum Intensity
text
C1519255 (UMLS CUI [1,1])
C1522410 (UMLS CUI [1,2])
C0518690 (UMLS CUI [1,3])
Maximum Intensity
Code List
Maximum Intensity
CL Item
Mild (1)
CL Item
Moderate (2)
CL Item
Severe (3)
CL Item
Not applicable (X)
Item
Action Taken with Investigational Product(s) as a Result of the SAE
text
C1547656 (UMLS CUI [1,1])
C4688482 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,3])
Action Taken with Investigational Product(s) as a Result of the SAE
Code List
Action Taken with Investigational Product(s) as a Result of the SAE
CL Item
Investigational product(s) withdrawn (1)
CL Item
Dose reduced (2)
CL Item
Dose increased (3)
CL Item
Dose not changed (4)
CL Item
Dose interrupted (5)
CL Item
Not applicable (X)
Withdrawal
Item
Did the subject withdraw from study as a result of this SAE?
boolean
C1547656 (UMLS CUI [1,1])
C1710677 (UMLS CUI [1,2])
C1519255 (UMLS CUI [1,3])
Relationship to Investigational Product(s)
Item
Is there a reasonable possibility the SAE may have been caused by the investigational product?
boolean
C0332149 (UMLS CUI [1,1])
C4688482 (UMLS CUI [1,2])
C0678227 (UMLS CUI [1,3])
C1519255 (UMLS CUI [1,4])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial